NovaDel Pharma’s loss from operations was $1.52m, compared to $1.28m for the comparable period in 2009.
For the nine months ended 30 September 2010, NovaDel has posted a net income of $3.73m, or $0.04 loss per diluted share, compared to a net loss of $5.2m, or $0.09 loss per diluted share, for the year ago period.
Loss from operations was $4.12m, compared to $4.79m for the year ago period.
NovaDel Pharma is a specialty pharmaceutical company developing oral spray formulations for marketed pharmaceutical products.
